Cipher Pharmaceuticals Inc.

Presenter: Larry Andrews, President & CEO

Company Information

Company Type: Pharmaceuticals

Development Stage: Public

Company Profile

ipher Pharmaceuticals Inc. is a commercial-stage specialty pharmaceutical company focused on commercializing novel formulations of successful, currently marketed molecules using advanced drug delivery technologies.

Cipher's strategy is to in-license products that incorporate proven drug delivery technologies and advance them through the clinical development and regulatory approval stages, after which the products are out-licensed to international partners. Because Ciphers products are based on proven technology platforms applied to currently marketed drugs, they are expected to have lower approval risk, shorter development timelines and reduced development costs. Integral to this strategy is the strength of the Company's partnerships as well as the management team's experience in product selection and licensing, pharmaceutical portfolio management, and clinical and regulatory affairs.

Cipher currently has three drugs in its portfolio. The Company's lead compound (CIP-FENOFIBRATE) is being marketed in the United States by Kowa Pharmaceuticals under the label Lipofen®. In addition, Cipher is developing formulations of the pain reliever tramadol (tentative FDA approval in February 2009) and the acne treatment isotretinoin (FDA approvable letter in April 2007).

Management Team

Larry Andrews, President and CEO

Norman Evans, C.A.. Chief Financial Officer

Jason A. Gross, Pharm.D., Vice President, Scientific Affairs

John MacInnis, Vice President, Portfolio Development and Licensing

Presenter Bio

Presenter Bio
Mr. Andrews is an accomplished senior executive with more than 25 years of experience in the pharmaceutical industry. The former President of AltiMed Pharmaceuticals, Mr. Andrews has played a lead role in the licensing of over 25 compounds in the Canadian pharmaceutical market and has marketed both innovative and generic products. His career includes senior management assignments with Eli Lilly, Syntex Pharmaceuticals, and Hoffmann-La Roche. He received his Honors BSc degree from Memorial University before joining the pharmaceutical industry.

Contact

Cipher Pharmaceuticals Inc.
5650 Tomken Rd., Unit 16
Mississauga
Ontario, Canada
L4W 4P1

ph: 905-602-5840
fx: 905-602-0628

www.cipherpharma.com
landrews@cipherpharma.com